Nymox Pharmaceutical (Nymox Pharmaceutical) EV-to-Revenue : -5,583.00 (As of Apr. 24, 2024)

View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nymox Pharmaceutical's enterprise value is $27.92 Mil. Nymox Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.01 Mil. Therefore, Nymox Pharmaceutical's EV-to-Revenue for today is -5,583.00.

The historical rank and industry rank for Nymox Pharmaceutical's EV-to-Revenue or its related term are showing as below:

NYMXF' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.76 Med: 481.12 Max: 3741.74
Current: -5583

During the past 13 years, the highest EV-to-Revenue of Nymox Pharmaceutical was 3741.74. The lowest was 3.76. And the median was 481.12.

NYMXF's EV-to-Revenue is ranked worse than
100% of 1032 companies
in the Biotechnology industry
Industry Median: 7.64 vs NYMXF: -5583.00

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-24), Nymox Pharmaceutical's stock price is $0.32. Nymox Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.00. Therefore, Nymox Pharmaceutical's PS Ratio for today is .

Nymox Pharmaceutical EV-to-Revenue Historical Data

The historical data trend for Nymox Pharmaceutical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical EV-to-Revenue Chart

Nymox Pharmaceutical Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EV-to-Revenue

Get a 7-Day Free Trial

256.79

1,306.80

38,031.76

Nymox Pharmaceutical Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EV-to-Revenue	Get a 7-Day Free Trial															-7,074.12	-	-6,107.62	-3,602.67	-9,779.83

Competitive Comparison of Nymox Pharmaceutical's EV-to-Revenue

For the Biotechnology subindustry, Nymox Pharmaceutical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nymox Pharmaceutical's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's EV-to-Revenue falls into.

Nymox Pharmaceutical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Nymox Pharmaceutical's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	27.915	/	-0.005
	=	-5,583.00

Nymox Pharmaceutical's current Enterprise Value is $27.92 Mil.
Nymox Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Nymox Pharmaceutical (OTCPK:NYMXF) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Nymox Pharmaceutical's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	0.32	/	0
	=

Nymox Pharmaceutical's share price for today is $0.32.
Nymox Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

Nymox Pharmaceutical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bay & Deveaux Streets, Nassau, BHS

Website

https://www.nymox.com

Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.

Executives

James George Robinson	director	10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen	officer: Chief Financial Officer	9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback	director, 10 percent owner, officer: CEO	C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham	director, officer: General Counsel